Combined CRISPR/Cas9- based gene editing of anti-CD19 CAR T cells with mediated disruption of PD-1 resulted in augmented killing efficacy of the CRISPR/Cas9-edited CAR T cells in vitro and potently cleared PD-L1+ tumor xenografts in vivo [93]. This evidence concerns the gene CD274 and neoplasm.